Small molecule anti-infective drugs are used for the treatment of various infectious diseases such as Methicillin-resistant Staphylococcus aureus (MRSA) infections, Methicillin-Susceptible Staphylococcus aureus (MSSA) infections, sinusitis, cellulitis, pneumonia, tuberculosis, aspergilosis, and hepatitis. Anti-infective drugs have the capability to eliminate and suppress infections that are caused by various bacteria and viruses.

Small Molecule Anti-infective Drug Market Drivers

Increasing approval of new drugs is expected to drive growth of the global small molecule anti-infective drug market. For instance, in April 2019, the U.S. Food and Drug Administration (FDA) announced the approval of Dovato (dolutegravir and lamivudine), which is used for the treatment of HIV-1 infection in adults. It is manufactured by ViiV Healthcare.

Furthermore, in August 2018, Tetraphase Pharmaceuticals received the U.S. Food and Drug Administration approval for its new drug, Xerava containing Eravacycline, which is used for the treatment of complicated intra-abdominal infections (CIAI).

Small Molecule Anti-infective Drug Market Restraints

Increasing severe side effect of drugs is the major restraining factor of anti-infective drug market, it is expected to the hamper the small molecule anti-infective drug market growth. For instance, NBC news report in December 2018, U.S Food and drug administration sends warning letters to Fluroquinonolone antibiotics because U.S FDA found that Fluroquinolones antibiotic can increase the occurrence of serious events of rupture in the main artery of the body. These ruptures called as the aortic dissections.

Small Molecule Anti-infective Drug Market Regional Analysis

On the basis of region, the global small molecule anti-infective drug market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

North America is expected to hold dominant position in the small molecule anti-infective drugs market, owing to new product launches of small molecule anti-infective drugs. For instance, in November 2018, Xellia Pharmaceuticals launched its new product, Vancomycine Hydrochloride for injection, in the U.S market.

Furthermore, Asia Pacific is also projected to witness significant growth in the global small molecule anti-infective drugs market, owing to increasing collaboration activities among key players. For instance, in April 2018, Entasis Therapeutics Holdings Inc. collaborated with the Zai Lab Limited. This collaboration facilitated phase III clinical trial for a fixed-dose combination of ETX2514 and sulbactam. This combination is intended for the treatment of multidrug-resistant infections caused by Acinetobacter baumannii bacteria. The study started in April 2019 and is expected to complete in July 2020.

Key players operating in the global small molecule anti-infective market include, Merck & Co., Inc., AstraZeneca, Theravance Biopharma, Bristol-Myers Squibb Company, Novartis AG, Bayer AG, Pfizer, Inc., Sanofi, GlaxoSmithKline plc. (GSK),and Allergan plc. 

Small Molecule Anti-infective Drug Market Taxonomy

 By Product Type

  • Antibiotics
    • B Lactam
    • Quinolones
    • Macrolides
    • Tetracyclines
    • Aminoglycosides
    • Sulphonamide
    • Others
  • Antifungal Drugs
    • Azoles
    • Echinocandins
    • Polyenes
    • Others
  • Antiviral Drugs
    • Nucleoside Reverse Transcriptase Inhibitors,
    • Non-nucleoside Reverse Transcriptase Inhibitor
    • Others
  • Others
    • Anthelminthic
    • Antiprotozoal

By Indication

  • Pneumonia
  • MRSA Infections
  • MSSA Infections
  • Sinusitis
  • Tuberculosis
  • Dermatophytosis
  • Aspergillosis
  • Candidiasis
  • Hepatitis
  • HIV Infection
  • Respiratory Tract Infection
  • Urinary Tract Infection
  • Others

By Distribution Channels

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
N/A